What is feasible for one person may be unaffordable for another, said Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor, Midwestern University Chicago College of Pharmacy, who practices at the Northwestern Medicine Infectious Disease Center.
What is feasible for one person may not be affordable for another, even for $10 vs $100, and these are conversations that should start before patients arrive to the pharmacy and are met with possible sticker shock, said Milena Murray, PharmD, MSc, BCIDP, AAHIVP, associate professor at Midwestern University Chicago College of Pharmacy, who practices at the Northwestern Medicine Infectious Disease Center in Chicago.
Transcript
How can we improve access to care for high-risk patients who have trouble affording their antiretroviral therapy or pre-exposure prophylaxis medications?
So this should really be a conversation that starts at the prescriber’s office when the prescription is sent and setting that expectation that if the cost is not feasible, that they need to call right away; like, don’t not pick up the prescription and then come back in 3 months and say, “Oh, it was, you know, I couldn’t afford to pick it up.” And I prefer to use that term feasible because expensive might be $10 for someone vs $100 for someone else. So even if the medication is $10, and they can’t afford it, that’s not feasible for them. So I really like that terminology.
We don’t want anyone to have sticker shock at the pharmacy and just say, “Nope, not getting it,” turn around, come out, maybe not even come back to the doctor’s office because they’re like, “Well, this doctor wants me on a therapy that’s $2500 a month,” when maybe that just needed a prior authorization and they didn’t understand that.
And I think it’s important to normalize the need for patient assistance programs, whether it’s through grants or co-payment assistance or through the manufacturer. The goal for everybody is to get that payment down to zero, regardless of their socioeconomic status.
As Claims Denials Surge, AI and Data-Driven Insights Equip Clinicians, Hospitals to Fight Back
March 13th 2025As health care costs continue to rise and the burden of chronic disease grows, data-driven insights will be essential in shaping the future of patient care, according to experts from Komodo Health and SmarterDx.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More